Lacutamab is under clinical development by Innate Pharma and currently in Phase II for Follicular Lymphoma. According to GlobalData, Phase II drugs for Follicular Lymphoma have a 45% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how Lacutamab’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Lacutamab (IPH-4102) is under development for the treatment of relapsed and refractory sezary syndrome (SS),cutaneous T-cell lymphomas such as transformed mycosis fungoides (TMF),and relapsed and refractory including angioimmunoblastic T-cell lymphoma (AITL), anaplastic large cell lymphoma (ALCL), follicular T-cell lymphoma, nodal peripheral T-cell lymphoma with TFH phenotype, adult T-cell leukemia/lymphoma (ATL), hepatosplenic T-cell lymphoma (HSTL), enteropathy-associated T-cell lymphoma (EATL), monomorphic epitheliotropic intestinal T cell lymphoma (MEITL), NK-T cell lymphoma (NKT) and aggressive NK-cell leukemia (ANKL). It was administered intravenously. The drug candidate is a cytotoxic antibody against KIR3DL2-expressing cancers.
Innate Pharma overview
Innate Pharma develops antibodies to treat cancer by harnessing the immune system. It offers Lumoxiti, a CD22-directed immunotoxin for the treatment of relapsed or refractory (r/r) hairy cell leukemia. The company is investigating Lacutamab, an anti-KIR3DL2 humanized cytotoxicity-inducing antibody for cutaneous T-cell lymphoma (CTCL), Monalizumab, an immune checkpoint inhibitor targeting solid tumors. Innate Pharma is also evaluating IPH5201, IPH5301, IPH6101, IPH6401, IPH6501 and IPH62 antibodies for the treatment of various of tumors. It works in partnership with Sanofi SA, AstraZeneca Plc and other biopharmaceutical companies to develop its products. Innate Pharma is headquartered in Marseille, Provence Alpes Cote d’Azur, France.
For a complete picture of Lacutamab’s drug-specific PTSR and LoA scores, buy the report here.